Enliven Therapeutics
ELVN
ELVN
26 hedge funds and large institutions have $7.76M invested in Enliven Therapeutics in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
70% less capital invested
Capital invested by funds: $26.2M → $7.76M (-$18.4M)
Holders
26
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$96.1K | |
| 2 | +$47.7K | |
| 3 | +$22K | |
| 4 |
BlackRock
New York
|
+$19K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$14K |
Top Sellers
| 1 | -$2.81M | |
| 2 | -$696K | |
| 3 | -$370K | |
| 4 |
LCM
Laurion Capital Management
New York
|
-$292K |
| 5 |
Two Sigma Investments
New York
|
-$153K |